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Abstract
Primary sclerosing cholangitis (PCS) is a progressive disease leading to secondary biliary cirrhosis. Patients are at increased
risk of developing cholangiocarcinoma, which is usually diagnosed at an advanced stage. Treatment of PCS includes medical
therapy, endoscopic biliary dilation, percutaneous transhepatic stenting, extrahepatic biliary resection and liver
transplantation. The most effective management of primary sclerosing cholangitis before the onset of cirrhosis remains
unclear. Non-transplant surgical procedures have a limited but defined role in patients with PCS. Resection of the
extrahepatic biliary tree in symptomatic non-cirrhotic patients improves hyperbilirubinaemia and prolongs both transplant-
free and overall survival when compared with non-operative dilation and/or stenting. Surgical resection may also definitively
establish or exclude a diagnosis of cholangiocarcinoma in patients with dominant extrahepatic or perihilar strictures.
Extrahepatic bile duct resection may also reduce the risk of cholangiocarcinoma. Extrahepatic biliary resection should be
considered in selected non-cirrhotic patients with symptomatic biliary obstruction and dominant extrahepatic and/or perihilar
strictures. Those patients in whom cholangiocarcinoma is suspected should also undergo resection.
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Introduction
Primary sclerosing cholangitis (PSC) is a progressive
chronic inflammatory disease of the intra- and extra-
hepatic biliary tree resulting in multifocal biliary
strictures, chronic cholestasis and eventual cirrhosis.
PSC is most commonly associated with inflammatory
bowel disease, and it may be diagnosed in up to 8% of
patients with ulcerative colitis. Patients are at increased
risk for developing cholangiocarcinoma, with a
reported lifetime prevalence of 10–30% [1]. These
cholangiocarcinomas are usually diagnosed at an
advanced stage, and the likelihood that they will be
resectable is quite low. The natural history of patients
with PSC is variable; many patients remain asympto-
matic for years, yet others will rapidly develop
advanced disease. Most patients with PSC will develop
symptoms of fatigue, itching and jaundice within
several years of diagnosis. Progression to portal
hypertension and cirrhosis ensues, and once liver
failure develops, liver transplantation is the only
therapeutic option. PSC is currently the fourth leading
indication for liver transplantation in adults in the
USA. For patients early in the course of their disease,
however, the most effective management remains
controversial.
Multiple treatment options exist for patients with
PSC and symptomatic biliary strictures. Surgical
resection has been used in patients with PSC with
varying degrees of success [2–8]. Medical therapy
has also been utilized but with no proven benefit
in outcome [9–15]. In addition, several non-operative
modalities have been used to relieve symptoms and
improve overall liver function. Endoscopic balloon
dilation with or without stenting and percutaneous
transhepatic stenting have become commonly used
techniques in managing biliary obstruction in the
setting of PSC [16–20]. To date there is no clear-cut
evidence that any of these treatment modalities can
slow the progression of PSC to cirrhosis. This review
will discuss the treatment options for PSC, focusing on
the role of non-transplant biliary tract surgery in the
management of this disease.
Non-operative management
Although numerous randomized trials examining a
variety of medical therapies for PSC have been
reported, no drug has demonstrated that it can slow
the progression of the disease to cirrhosis or produce
clinically meaningful symptomatic improvement.
Ursodeoxycholic acid has been the most extensively
studied drug and has been shown to improve serum
liver function tests and the histological stage of disease
on liver biopsy. However, no difference in clinical
outcome has been observed [9,10]. Many other agents
have also been evaluated including methotrexate,
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tacrolimus, cladibrine, budesonide and colchicine.
None of these agents has demonstrated any significant
improvement in symptoms or outcome [11–15].
Endoscopic balloon dilation or stenting is being
increasingly utilized to relieve biliary obstruction in
patients with PSC [16–18]. Such therapy seems most
beneficial for patients with one or more dominant
extrahepatic strictures (defined as a stricture of
the common bile duct or common hepatic duct with
a diameter of41.5 mm and/or a stricture of a hepatic
duct with a diameter of 41.0 mm within 2 cm of the
hepatic duct bifurcation). The incidence of dominant
strictures in patients with PSC is approximately 45%
[21]. Stiehl et al. prospectively studied 106 patients
treated with ursodeoxycholic acid [22]. Over a 5-year
period, 52 patients developed dominant stenoses and
were managed endoscopically. The actuarial survival
free of liver transplantation at 5 years was significantly
better than predicted with the Mayo multicentre
survival model (94% vs 77%). Baluyut et al. also
demonstrated a significantly higher 5-year survival rate
than the predicted 5-year survival (83% vs 65%) in 63
patients undergoing endoscopic therapy over a 6-year
period [23]. More long-term studies are needed to fully
evaluate the benefit of endoscopic biliary dilation.
Dilation of biliary strictures can also be performed
percutaneously [19,20]. This technique is most
advantageous for patients with intrahepatic or perihilar
biliary strictures not amenable to endoscopic ap-
proaches, as well as for preoperative stent placement
and postoperative dilation and stenting of proximal
intrahepatic or anastomotic strictures. However,
percutaneous biliary drainage is technically more
difficult to perform, and is associated with a higher
rate of complications including cholangitis, haemobilia
and intra-abdominal abscess.
Non-transplant surgical management
Surgical resection
Prior to the widespread use of liver transplantation and
endoscopic balloon dilation to manage PSC, surgical
resection was used as the predominant method of
treatment. Over the past 15 years, several centres
have reported good results after extrahepatic biliary
resection or bypass, with long-term improvement in
jaundice and survival in non-cirrhotic patients [2–4,6].
Operative management of PSC entails resection of the
extrahepatic biliary tree including the hepatic duct
bifurcation and postoperative transhepatic stenting.
The operative approach for patients with PSC is based
on the observation that the hepatic duct bifurcation is
frequently involved with a dominant stricture [24].
Percutaneous transhepatic biliary stents are placed
preoperatively to serve as technical aids at the time of
exploration. The extrahepatic biliary tree and the
hepatic duct bifurcation are then resected, and bilateral
hepaticojejunostomies are constructed over Silastic
stents. The transhepatic stents are removed at 1 year if
there is free flow across the biliary enteric anastomosis
(Figure 1).
Symptomatic biliary obstruction
The largest published non-transplant surgical experi-
ence in the management of patients with PSC is from
the Johns Hopkins Hospital [6]. Between 1980 and
1994, 146 patients with PSC were treated at Johns
Hopkins. Fifty patients underwent resection of
the extrahepatic biliary tract; 40 of these patients were
non-cirrhotic. Mean follow-up was 62 months. All
patients had symptomatic biliary obstruction, and
the primary indications for treatment were persistent
jaundice and cholangitis. Operative mortality in
patients with and without cirrhosis was 20% and
2.5%, respectively. Postoperative complications
A
B
Figure 1. (A) Preoperative cholangiogram from a 45-year-old female
with primary sclerosing cholangitis, who was referred following a
cholecystectomy and placement of a t-tube for acute cholecystitis and
cholangitis. She remained jaundiced postoperatively. The cholan-
giogram demonstrates distal common bile duct, perihilar and
intrahepatic strictures. She was managed with resection of the
extrahepatic bile duct and hepatic duct bifurcation. (B) Post-
operative cholangiogram demonstrates patent bilateral hepatico-
jejunostomies. The stents were removed 1 year postoperatively.
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developed in 32% of patients, the most common being
cholangitis. The overall 1-, 3- and 5-year survival rates
after bile duct resection were 86%, 84% and 76%,
respectively (Table I). Patients without cirrhosis had
1-, 3- and 5-year survival rates of 95%, 92% and 85%,
respectively. Biliary resection also significantly reduced
serum bilirubin levels at 1, 2 and 3 years after resection
when compared with preoperative levels. None of
the resected patients developed cholangiocarcinoma
during a mean follow-up of 62 months.
This analysis is the only study comparing the
long-term results of extrahepatic bile duct resection
with endoscopic and other non-operative therapies in
the same clinical setting. Endoscopic balloon dilation
was performed in 35 patients with PSC and sympto-
matic biliary obstruction between 1990 and 1994. The
overall complication rate was 14%, the most common
being mild pancreatitis. Overall survival for resected
patients was significantly longer than for patients
managed with endoscopic dilation or with both
endoscopic and percutaneous biliary drainage meth-
ods. The overall 5-year survival rate in non-cirrhotic
patients managed with endoscopic dilation was
58%, significantly lower than the 5-year survival after
resection (85%). Similarly, transplant-free survival
was also longer for patients treated operatively when
compared with patients treated non-operatively. Three
of 35 patients (8%) treated endoscopically developed
cholangiocarcinoma.
Several other centres have reported excellent results
with extrahepatic biliary resection in patients with
primary sclerosing cholangitis. Myburgh reported
results with the Hepp-Couinaud hepaticojejunostomy
in PSC patients [4]. Actuarial survival in the 16
patients without cirrhosis managed with this approach
was 100% with a median follow-up of 6.5 years. This
approach leaves in situ the extrahepatic biliary tree,
with its malignant potential, but clearly improves the
natural history of this disease in patients with dominant
hilar and extrahepatic strictures.
Hutson et al. have recently reviewed their experience
with serial dilations of the biliary tree through a
subcutaneously placed afferent limb of a choledocho-
jejunostomy in patients with PSC [25]. This prospec-
tive 15-year evaluation included 36 patients treated by
repeat dilatation. Operative mortality was 3% and only
one major complication occurred during dilatation.
The 5-year survival of all patients was 74%. If patients
with cirrhosis or unsuspected cholangiocarcinoma at
the time of operation were not included, the 5-year
survival was 86%. The 15-year survival of all patients
was 30% and was 64% if those with cirrhosis and
unsuspected cholangiocarcinoma at the time of opera-
tion were not included. Six patients remained alive with
an average survival of 159 months. Repeated dilatation
of biliary strictures in patients with sclerosing cholan-
gitis through a subcutaneously placed afferent limb of a
choledochojejunostomy is technically feasible and safe.
This study suggests that a combination of choledocho-
jejunostomy with repeated dilatations combined with
later liver transplantation is the approach of choice in
selected patients. Two additional recent case reports
have also demonstrated long-term survival with surgi-
cal management of PSC [26,27].
Thus, in carefully selected patients without
significant hepatic fibrosis and with predominantly
extrahepatic biliary strictures, resection of the extra-
hepatic biliary tree may prolong the interval to liver
transplantation and provide relief of jaundice.
Cholangiocarcinoma
Surgical resection also plays a critical role in the
management of patients with a confirmed diagnosis
of or suspected cholangiocarcinoma. Cholangiocarci-
noma is the most feared complication of PSC and is a
major cause of death in patients with PSC. The disease
develops in approximately 10–15% of PSC patients
followed for 5 years and up to 30% of patients followed
for410 years [28]. Widespread biliary strictures make
cholangiographic diagnosis of cholangiocarcinoma
difficult. Methods for early detection have been
studied, such as the tumour markers CA 19-9 and
CEA, as well as cytologic brushings from ERCP. A
recent study suggests that CA 19-9, when used in
conjunction with available tests, aids in the differential
diagnosis of cholangiocarcinoma [29]. Biliary cytology
has a high false negative rate for the diagnosis of
cholangiocarcinoma in the setting of PSC. Despite the
more widespread use of tumour markers in the
surveillance of patients with PSC, these screening
techniques are inadequate and most patients diagnosed
with cholangiocarcinoma in the setting of PSC present
with unresectable disease.
We previously reviewed the experience with cholan-
giocarcinoma complicating PSC at Johns Hopkins
[30]. Among the 139 patients with PSC treated
between 1984 and 1997, 25 patients (18%) were
diagnosed with cholangiocarcinoma. Fourteen of these
Table I. Overall and transplant-free survival by treatment method in
non-cirrhotic patients with primary sclerosing cholangitis
Patients n Risk score
Actuarial survival (%)
1 year 3 year 5 year
Overall survival
Resection 40 3.36+0.12 95 92 85
ES/BD 26 3.13+0.27 88 72* 58*
Percutaneous stenting 17 3.59+0.28 87 79* 63
Combined non-operative 43 3.27+0.21 87 74# 59#
Transplant-free survival
Resection 40 3.36+0.12 95 95 82
ES/BD 26 3.13+0.27 83 56* 42*
Percutaneous stenting 17 3.59+0.28 87 64# 51#
Combined non-operative 43 3.27+0.21 85 59* 46*
ES/BD, endoscopic sphincterotomy/balloon dilation. *p50.01
versus resection; #p50.05 versus resection. Adapted from Ahrendt
et al. [6].
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25 patients (56%) were diagnosed within 1 year of
the diagnosis of PSC. Serum CA 19-9 was elevated
in all six patients with cholangiocarcinoma who were
analysed and in none of eight patients without
cholangiocarcinoma. Serum CEA was elevated in only
half the patients with cholangiocarcinoma and was
normal in 8 of 10 patients without cholangiocarci-
noma. Of nine patients with cholangiocarcinoma that
were deemed resectable, five were managed with either
extrahepatic bile duct resection and/or partial hepatic
resection and four underwent liver transplantation.
The remaining 16 patients were unresectable at pre-
sentation. Actuarial 1- and 3-year survival rates in the
resected patients were 56% and 28%, respectively,
compared with 13% and 0% in the unresected patients.
In the Johns Hopkins experience, none of the
patients with PSC managed with extrahepatic biliary
resection later developed cholangiocarcinoma [6].
Natural history data suggest that seven or eight of
these patients should have developed a bile duct
malignancy [7]. Resection of the entire extrahepatic
biliary tree including the hepatic duct bifurcation
in 80% of these patients may have reduced their
risk of developing cholangiocarcinoma. In contrast,
cholangiocarcinoma has been reported in most series of
patients undergoing endoscopic dilation for PSC,
underscoring the difficulty of diagnosing the disease
in these patients. Of 106 patients in Stiehl’s series
3% developed cholangiocarcinoma, while 8% of the
63 patients in Baluyut’s study were diagnosed with
cholangiocarcinoma [22,23]. Incidental cholangio-
carcinomas discovered at the time of liver transplanta-
tion are most often located at the hepatic duct
bifurcation (72% of the time), and only 11% are
intrahepatic [31]. This distribution supports the
potential role of bifurcation resection in lowering the
risk of cholangiocarcinoma in PSC patients. The lower
incidence of cholangiocarcinoma in the surgically
resected patients may have been responsible, in part,
for the greater overall survival in the non-cirrhotic
patients managed with this technique versus endo-
scopic balloon dilation [6].
Because the early diagnosis of cholangiocarcinoma
remains elusive, extrahepatic bile duct resection
should be considered in patients with PSC in whom
the diagnosis of cholangiocarcinoma is suspected but
not proven. In many patients, cholangiocarcinoma is
identified soon after the initial diagnosis of PSC, and
clinical suspicion must be high at this time. Dominant
strictures that recur or persist after endoscopic dilation
should be resected to exclude the possibility of
cholangiocarcinoma [32]. Patients may also be diag-
nosed with PSC after the pathological evaluation of a
resected isolated biliary stricture is benign and has the
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Figure 2. Treatment algorithm for the management of patients with primary sclerosing cholangitis (PSC). At the time of diagnosis patients
with PSC should be staged to determine the severity of liver fibrosis. Patients should also be screened for cholangiocarcinoma at the time of
diagnosis and annually thereafter. Screening includes an ERCP with brush cytology, MRI, and/or serum CA 19-9. Extrahepatic bile duct
resection (EHBDR) should be considered in patients with dominant strictures and atypical or suspicious biliary cytology. H&P, history and
physical; ES/BD, endoscopic sphincterotomy/balloon dilation.
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characteristics of sclerosing cholangitis. A variety of
benign conditions including PSC can present with
an isolated biliary stricture mimicking cholangio-
carcinoma [33,34].
Summary
PSC is a progressive disease that eventually leads
to cirrhosis, portal hypertension and liver failure.
Management of the patient with PSC is based on a
careful assessment of the cholangiographic appearance
of the biliary tract, histological stage of disease on liver
biopsy and the presence of symptoms. Our manage-
ment approach to the patient with PSC is depicted
in Figure 2. Non-operative biliary dilation provides
symptomatic and biochemical improvement in pat-
ients, although this option results in shorter overall and
transplant-free survival than resection and may be
associated with a higher incidence of cholangiocarci-
noma. Resection of the hepatic duct bifurcation with
long-term transhepatic stenting should be considered
for selected non-cirrhotic patients who have sympto-
matic biliary obstruction and dominant extrahepatic
strictures – particularly in those who fail endoscopic
therapy. This approach has provided long-term
improvement in serum bilirubin levels and appears to
delay the need for liver transplantation in several
recent surgical series. Non-transplant biliary surgery
has not significantly increased the operative morbidity
and mortality of liver transplantation and should be
considered as a treatment option in patients with early
stage PSC [35]. Cholangiocarcinoma continues to be
a leading cause of mortality in patients with PSC.
Patients with dominant strictures and equivocal results
on cancer screening tests should be managed with
resection rather than prolonged efforts at cancer
diagnosis. Liver transplantation is clearly the best
treatment option once cirrhosis has developed.
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